Held by 10 specialist biotech funds
High Convergence# Signal Note: Avoro Capital Initiates $172.8M Position in RVMD Avoro's entry signals conviction in Revolution Medicines' RLY001 program, a potential first-in-class SHP2 inhibitor for RAS-driven cancers, which is advancing through Phase 2 studies with data readouts expected in 2024-2025.
AI analyst context — unlock full analysis
# Signal Note: Driehaus Initiates RVMD Position Driehaus Capital's $127K entry into Revolution Medicines signals conviction in the company's RLY-4008 (a selective RAS(G12C) inhibitor) pipeline, particularly for solid tumors where competitive positioning remains relevant despite existing KRAS inhibitors. The relatively modest position sizing suggests either a probe trade or conviction limited by near-term clinical/commercial risks; near-term catalysts likely include additional clinical data readouts for RLY-4008 and/or earlier-stage programs in the RAS pathway space.
+ 8more — see how much conviction went in
See the Full Story